poisar

Stocks · News reference

Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate

BenzingaAug 10, 2026, 11:45 AMBenzinga Newsdesk

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96) per share from the

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 10, 2026, 11:45 AM
Checked
Aug 10, 2026, 11:45 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARJun 24, 2026, 8:15 PMSEC EDGAR

    8-K filing — Passage BIO, Inc. (PASG)

    Filed: 2026-06-24 AccNo: 0001104659-26-077306 Size: 12 MB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    Read original at edgar